Prot #CP-MVC-101-01: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic

Project: Research project

Project Details

StatusActive
Effective start/end date4/22/24 → 4/22/27

Funding

  • PPD Investigator Services, LLC (Prot #CP-MVC-101-01 // Prot #CP-MVC-101-01)
  • Takeda Development Center Americas, Inc. (Prot #CP-MVC-101-01 // Prot #CP-MVC-101-01)